G-CSF

Type: Keyphrase
Name: G-CSF
First reported 1 hour ago - Updated 1 hour ago - 1 reports

Mobilization of healthy donors with plerixafor affects the cellular composition of T-cell receptor ...

HLA-haploidentical hematopoietic stem cell transplantation (HSCT) is suitable for patients lacking related or unrelated HLA-matched donors. Herein, we investigated whether plerixafor (MZ), as an adjunct to G-CSF, facilitated the collection of mega-doses ... [Published 7thSpace - 1 hour ago]
First reported 4 hours ago - Updated 4 hours ago - 1 reports

Granulocyte colony-stimulating factor off-target effect on nerve outgrowth promotes prostate cancer development - Abstract

The hematopoietic growth factor granulocyte colony-stimulating factor (G-CSF) has a role in proliferation, differentiation and migration of the myeloid lineage and in mobilizing hematopoietic stem and progenitor cells into the bloodstream.However, G-CSF ... [Published UroToday - 4 hours ago]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Mutation disables innate immune system

A Ludwig Maximilian University of Munich team has shown that defects in the JAGN1 gene inhibit the function of a specific type of white blood cells, and account for a rare congenital immune deficiency that increases vulnerability to life-threatening ... [Published Medical Xpress - Aug 29 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Green Cross Neulapeg biosimilar approved in South Korea

South Korea’s Green Cross says that the country’s Ministry of Food and Drug Safety has granted marketing authorization for Neulapeg (pegteograstim), a treatment for abnormally low level of neutrophils in patient undergoing chemotherapy.Neulapeg is a biosimilar ... [Published Pharma Letter - Aug 28 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

South Korean FDA Approval For Green Cross’ Neulapeg®

Tech & PharmaAugust 27, 2014Green Cross receives regulatory approval for its once-per-cycle dose neutropenia drug, Neulapeg®.AsianScientist (Aug. 27, 2014) – Green Cross, a South Korean biopharmaceutical company, has been granted South Korea’s Ministry ... [Published Asian Scientist - Aug 27 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

G-CSF therapy improved survival in patients with alcoholic hepatitis

Patients with severe alcoholic hepatitis treated with standard therapy plus granulocyte colony-stimulating factor had a greater survival rate after therapy compared with those treated without it, according to data from a recent study.Forty-six patients ... [Published Orthopedics Today - Aug 26 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

Anti-Obesity Effects of Granulocyte-Colony Stimulating Factor in Otsuka-Long-Evans-Tokushima Fatty Rats

by Yonggu Lee, Yi-Sun Song, Cheng-Hu Fang, Byung-Im So, Jun-Young Park, Hyun-Woo Joo, In-Hwa Park, Guang-Yin Shen, Jeong-Hun Shin, Hyuck Kim, You-Heon Ahn, Kyung-Soo KimGranulocyte-colony stimulating factor (G-CSF) has molecular structures and intracellular ... [Published Plosone.org - Aug 22 2014]
Entities: G-CSF, Anti-Obesity, Rats
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

Abbott To Develop Portable Blood Tests For Concussions

Summary Abbott joined forces with the United States Department of Defense for developing portable blood tests for concussions. The tests will help Abbott generate significant revenues not only from the military personnel, but also from civilian people ... [Published Seeking Alpha - Aug 21 2014]
First reported Aug 17 2014 - Updated Aug 17 2014 - 1 reports

Stem Cell Transplantation

Greco R, Bondanza A, Oliveira MC, Badoglio M, Burman J, Piehl F, Hagglund H, Krasulova E, Simões BP, Carlson K, Pohlreich D, Labopin M, Saccardi R, Comi G, Mancardi GL, Bacigalupo A, Ciceri F, Farge D. Autologous hematopoietic stem cell transplantation ... [Published Multiple Sclerosis Research - Aug 17 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 2 reports

Japan Recommends Long-Acting G-CSF Filgrastim

Article # 28140814010Posted: Aug. 15, 2014 2:35 AM GMTExecutive SummaryJapan recommended for approval two pharmaceutical products on August 8, including the new long-acting G-CSF formulation G-Lasta (genetic recombinant pegfilgrastim) from Kyowa Hakko ... [Published Health News Daily - Aug 15 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

Combinatorial G-CSF/AMD3100 Treatment in Cardiac Repair after Myocardial Infarction

by Constantin Rüder, Tobias Haase, Annalena Krost, Nicole Langwieser, Jan Peter, Stefanie Kamann, Dietlind ZohlnhöferAimsSeveral studies suggest that circulating bone marrow derived stem cells promote the regeneration of ischemic tissues. For hematopoietic ... [Published Plosone.org - Aug 14 2014]
First reported Aug 05 2014 - Updated Aug 06 2014 - 2 reports

RNCOS - Business Consulting Services: Emerging Markets to Play Pivotal Role in the Growth of Biosimilars

The ability of Biosimilars to act as growth engines by ensuring broader access to medicines and sustainability is helping biosimilars gain value in emerging economies. Countries such as India, China, Korea, Vietnam and Brazil are witnessing remarkable ... [Published BusinessWeek - Aug 06 2014]

Quotes

Single-dose MZ was given to 30 ` "poor mobilizers? (PM) failing to attain ?40 CD34+ HSCs/?L after 4 daily G-CSF doses and/or with predicted apheresis yields ?12.0x106 CD34+ cells/kg recipient?s body weight."
"Jagunal homolog 1 is a critical regulator of neutrophil function in fungal host defense." Gerald Wirnsberger, et al. Nature Genetics (2014) DOI: 10.1038/ng.3070...
...The study's lead author Cesar V Borlongan, PhD, said, "Our results showed that the combined therapy of hUBCs and G-CSF significantly reduced the TBI-induced loss of neuronal cells in the hippocampus."
NEXT ARTICLE More From BioPortfolio on "Sandoz International’s Zarxio on Path to Become First Official U S Biosimilar"

More Content

All (62) | News (52) | Reports (0) | Blogs (7) | Audio/Video (0) | Fact Sheets (2) | Press Releases (1)
sort by: Date | Relevance
Mobilization of healthy donors with plerixafor ... [Published 7thSpace - 1 hour ago]
Granulocyte colony-stimulating factor off-targe... [Published UroToday - 4 hours ago]
Mutation disables innate immune system [Published Medical Xpress - Aug 29 2014]
Early Activation of MAP Kinases by Influenza A ... [Published Plosone.org - Aug 28 2014]
Green Cross Neulapeg biosimilar approved in Sou... [Published Pharma Letter - Aug 28 2014]
South Korean FDA Approval For Green Cross’ Neul... [Published Asian Scientist - Aug 27 2014]
G-CSF therapy improved survival in patients wit... [Published Orthopedics Today - Aug 26 2014]
Anti-Obesity Effects of Granulocyte-Colony Stim... [Published Plosone.org - Aug 22 2014]
Abbott To Develop Portable Blood Tests For Conc... [Published Seeking Alpha - Aug 21 2014]
Deprived TLR9 Expression in Apparently Healthy ... [Published Plosone.org - Aug 19 2014]
Stem Cell Transplantation [Published Multiple Sclerosis Research - Aug 17 2014]
Japan Recommends Long-Acting G-CSF Filgrastim [Published Health News Daily - Aug 15 2014]
Japan Recommends Long-Acting G-CSF Filgrastim [Published BioPortfolio - Aug 15 2014]
Combinatorial G-CSF/AMD3100 Treatment in Cardia... [Published Plosone.org - Aug 14 2014]
Sandoz International’s Zarxio on Path to Become... [Published BioPortfolio - Aug 12 2014]
Intracutaneous paste composition [Published PharmCast - Aug 12 2014]
Cleveland BioLabs' (CBLI) CEO Yakov Kogan on Q2... [Published Seeking Alpha - Aug 07 2014]
FDA 'must publish biosimilar naming guide soon' [Published PMLive - Aug 06 2014]
RNCOS - Business Consulting Services: EPO Biosi... [Published BusinessWeek - Aug 06 2014]
RNCOS - Business Consulting Services: Emerging ... [Published BusinessWeek - Aug 06 2014]
Emerging Markets to Play Pivotal Role in the Gr... [Published MyNewsDesk - Aug 05 2014]
EPO Biosimilars: Reining the Biosimilars Market [Published MyNewsDesk - Aug 05 2014]
Decitabine Suspends Human CD34+ Cell Differenti... [Published Plosone.org - Aug 04 2014]
Teva’s 2nd-qtr sales and earnings miss analysts... [Published Pharma Letter - Aug 01 2014]
Scientists find protein-building enzymes have m... [Published HispanicBusiness.com - Jul 30 2014]
Autologous hematopoietic stem cell transplantat... [Published Multiple Sclerosis Journal RSS feed -- OnlineFi ... - Jul 30 2014]
Finally, A Biosimilar Application Has Been Acce... [Published JD Supra - Jul 29 2014]
Forum Post: RE: NUTROPHILS AT 0 [Published Macmillan Cancer Support - Jul 28 2014]
FDA Accepts the First Biosimilar Application un... [Published JD Supra - Jul 25 2014]
Sandoz application for biosimilar Neupogen acce... [Published Pharma Letter - Jul 25 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Stem Cell Transplantation [Published Multiple Sclerosis Research - Aug 17 2014]
Greco R, Bondanza A, Oliveira MC, Badoglio M, Burman J, Piehl F, Hagglund H, Krasulova E, Simões BP, Carlson K, Pohlreich D, Labopin M, Saccardi R, Comi G, Mancardi GL, Bacigalupo A, Ciceri F, Farge D. Autologous hematopoietic stem cell transplantation ...
Autologous hematopoietic stem cell transplantat... [Published Multiple Sclerosis Journal RSS feed -- OnlineFi ... - Jul 30 2014]
Background: Neuromyelitis optica (NMO) is an inflammatory autoimmune disorder of the central nervous system, hallmarked by pathogenic anti-aquaporin 4 antibodies. NMO prognosis is worse compared with multiple sclerosis. Objective: The European Group for ...
Research and Markets: World Market for Biosimil... [Published Business Wire Health News - Jul 23 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/xrwqsh/the_world_market) has announced the addition of the "The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)" ...
The World Market for Biosimlars (EPO, G-CSF, HG... [Published PR Newswire: Entertainment & Media - Jul 21 2014]
LONDON, July 21, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:The World Market for Biosimlars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th... ...
Research and Markets: The World Market for Bios... [Published Business Wire Health News - Jun 06 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/xp9knh/the_world_market) has announced the addition of the "The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, ...
1 2

Press Releases

sort by: Date | Relevance
Neumedicines Publishes Data Demonstrating that ... [Published GlobeNewswire: Sports News - Jun 02 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.